Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-11-1429
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Subcutaneous Rituximab in B-Cell Non-Hodgkin Lymphoma: A Single-Center Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Rituximab in the Treatment of B-Cell Non-Hodgkin Lymphoma, Focus on Outcomes and Comparative Effectiveness

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2010English

MicroRNA Dysregulation in B-Cell Non-Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2013English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma

Asian Pacific Journal of Cancer Prevention
2018English

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Autologous Stem Cell Transplantation Outcomes in Elderly Patients With B Cell Non-Hodgkin Lymphoma

British Journal of Haematology
Hematology
2015English

Synchronous Occurrence of B-Cell Non Hodgkin Lymphoma and Metastatic Small Cell Carcinoma of Lung

National Journal of Health Sciences
2017English

Choosing the Appropriate Salvage Therapy for B-Cell Non-Hodgkin Lymphoma

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy